# Parkinson's Pathways

> A free, family-friendly guide to every recruiting Parkinson's disease clinical trial. Currently tracking 538 trials.

## About

Parkinson's Pathways helps patients, caregivers, and clinicians find and understand Parkinson's clinical trials. Every trial is translated for families with a five-word goal, eligibility details, and nearby locations.

Two distinct content tiers are exposed here:

1. **PD Curated**: Parkinson's-only trials with AI-generated family-friendly summaries, five-word goals, geocoded sites, and recent site-change tracking.
2. **Universal Raw Mirror**: A larger, condition-agnostic mirror of ClinicalTrials.gov with no AI summaries and no editorial enrichment. Use this when you need source-of-truth raw data.

Selected content families expose clean Markdown twins (append `.md` to the URL) with YAML frontmatter, intended for LLM ingestion. Supported patterns: `/learn/{slug}.md`, `/caregivers.md`, `/caregivers/{slug}.md`, `/trial/{nctId}.md`, `/trials-near-me.md`, `/trials-near-me/{city}.md`, `/trials/{type}/{slug}.md`, `/trials/eu/{euctId}.md`. Pages such as `/`, `/about`, `/trials`, `/insights`, `/match`, and `/digest` do not have Markdown twins.

## Key Pages

- [Browse All Trials](https://parkinsonspathways.com/trials): Search and filter all 538 recruiting Parkinson's clinical trials by phase, study type, enrollment size, country, and age eligibility.
- [Trials Near Me](https://parkinsonspathways.com/trials-near-me): Find clinical trials near a specific location using zip code or city search.
- [Trial Outcomes & Results Tracker](https://parkinsonspathways.com/results): Completed, terminated, and withdrawn Parkinson's trials, with results and publications as they become available (Markdown twin at https://parkinsonspathways.com/results.md).
- [Insights Dashboard](https://parkinsonspathways.com/insights): Visual overview of the Parkinson's trial landscape, including phase breakdown, intervention types, top sponsors, eligibility stats, and a global map.
- [Learn](https://parkinsonspathways.com/learn): Educational articles explaining clinical trial concepts, translated for families.
- [For Caregivers](https://parkinsonspathways.com/caregivers): Family-first guides for Parkinson's caregivers, medication routines, burnout, legal and financial paperwork, and the care partner's role in clinical trials.
- [About](https://parkinsonspathways.com/about): The story behind the project and how it works.

## PD Curated: Learn Articles (Markdown twins)

Each article is available as both HTML (for humans) and Markdown (for LLM ingestion). Markdown URLs include YAML frontmatter with title, description, canonical URL, and publication date.

- Why I Built Parkinson's Pathways, HTML: https://parkinsonspathways.com/learn/why-i-built-parkinsons-pathways, Markdown: https://parkinsonspathways.com/learn/why-i-built-parkinsons-pathways.md
- What Do Clinical Trial Phases Mean?, HTML: https://parkinsonspathways.com/learn/what-do-clinical-trial-phases-mean, Markdown: https://parkinsonspathways.com/learn/what-do-clinical-trial-phases-mean.md
- What Do Clinical Trial Statuses Mean?, HTML: https://parkinsonspathways.com/learn/what-do-clinical-trial-statuses-mean, Markdown: https://parkinsonspathways.com/learn/what-do-clinical-trial-statuses-mean.md
- How Long Does a Parkinson's Clinical Trial Last?, HTML: https://parkinsonspathways.com/learn/how-long-does-a-parkinsons-clinical-trial-last, Markdown: https://parkinsonspathways.com/learn/how-long-does-a-parkinsons-clinical-trial-last.md
- How to Talk to Your Neurologist About Clinical Trials, HTML: https://parkinsonspathways.com/learn/how-to-talk-to-your-neurologist-about-clinical-trials, Markdown: https://parkinsonspathways.com/learn/how-to-talk-to-your-neurologist-about-clinical-trials.md
- How to Spot a Questionable Clinical Trial, HTML: https://parkinsonspathways.com/learn/how-to-spot-a-questionable-clinical-trial, Markdown: https://parkinsonspathways.com/learn/how-to-spot-a-questionable-clinical-trial.md
- Just Diagnosed with Parkinson's? Where to Start with Clinical Trials, HTML: https://parkinsonspathways.com/learn/just-diagnosed-with-parkinsons-clinical-trials, Markdown: https://parkinsonspathways.com/learn/just-diagnosed-with-parkinsons-clinical-trials.md
- Stem Cell Therapy for Parkinson's: What You Should Actually Know, HTML: https://parkinsonspathways.com/learn/stem-cell-therapy-for-parkinsons, Markdown: https://parkinsonspathways.com/learn/stem-cell-therapy-for-parkinsons.md
- Will My Family Member Get a Placebo?, HTML: https://parkinsonspathways.com/learn/will-my-family-member-get-a-placebo, Markdown: https://parkinsonspathways.com/learn/will-my-family-member-get-a-placebo.md
- How Close Is a Cure for Parkinson's Disease?, HTML: https://parkinsonspathways.com/learn/how-close-is-a-cure-for-parkinsons, Markdown: https://parkinsonspathways.com/learn/how-close-is-a-cure-for-parkinsons.md
- Parkinson's and Dementia: Clinical Trials Families Should Know, HTML: https://parkinsonspathways.com/learn/parkinsons-and-dementia-clinical-trials, Markdown: https://parkinsonspathways.com/learn/parkinsons-and-dementia-clinical-trials.md
- What Is Levodopa and How Does It Work?, HTML: https://parkinsonspathways.com/learn/what-is-levodopa-and-how-does-it-work, Markdown: https://parkinsonspathways.com/learn/what-is-levodopa-and-how-does-it-work.md
- What to Expect in the First Year After Diagnosis, HTML: https://parkinsonspathways.com/learn/what-to-expect-first-year-after-parkinsons-diagnosis, Markdown: https://parkinsonspathways.com/learn/what-to-expect-first-year-after-parkinsons-diagnosis.md
- Diet and Parkinson's Risk: What the Research Says, HTML: https://parkinsonspathways.com/learn/diet-and-parkinsons-risk, Markdown: https://parkinsonspathways.com/learn/diet-and-parkinsons-risk.md
- ClinicalTrials.gov vs Parkinson's Pathways, HTML: https://parkinsonspathways.com/learn/clinicaltrials-gov-vs-parkinsons-pathways, Markdown: https://parkinsonspathways.com/learn/clinicaltrials-gov-vs-parkinsons-pathways.md
- Interventional vs Observational Parkinson's Trials, HTML: https://parkinsonspathways.com/learn/interventional-vs-observational-parkinsons-trials, Markdown: https://parkinsonspathways.com/learn/interventional-vs-observational-parkinsons-trials.md
- Phase 1 vs Phase 2 vs Phase 3 Trials, HTML: https://parkinsonspathways.com/learn/phase-1-vs-phase-2-vs-phase-3-trials, Markdown: https://parkinsonspathways.com/learn/phase-1-vs-phase-2-vs-phase-3-trials.md
- Disease-Modifying vs Symptomatic Parkinson's Trials, HTML: https://parkinsonspathways.com/learn/disease-modifying-vs-symptomatic-parkinsons-trials, Markdown: https://parkinsonspathways.com/learn/disease-modifying-vs-symptomatic-parkinsons-trials.md
- Industry-Sponsored vs Academic Parkinson's Trials, HTML: https://parkinsonspathways.com/learn/industry-sponsored-vs-academic-parkinsons-trials, Markdown: https://parkinsonspathways.com/learn/industry-sponsored-vs-academic-parkinsons-trials.md
- Clinical Trial vs Standard of Care, HTML: https://parkinsonspathways.com/learn/clinical-trial-vs-standard-of-care-parkinsons, Markdown: https://parkinsonspathways.com/learn/clinical-trial-vs-standard-of-care-parkinsons.md
- dbs-vs-duopa-vs-focused-ultrasound-parkinsons, HTML: https://parkinsonspathways.com/learn/dbs-vs-duopa-vs-focused-ultrasound-parkinsons, Markdown: https://parkinsonspathways.com/learn/dbs-vs-duopa-vs-focused-ultrasound-parkinsons.md
- parkinsons-vs-lewy-body-dementia-vs-psp-vs-msa, HTML: https://parkinsonspathways.com/learn/parkinsons-vs-lewy-body-dementia-vs-psp-vs-msa, Markdown: https://parkinsonspathways.com/learn/parkinsons-vs-lewy-body-dementia-vs-psp-vs-msa.md
- parkinsons-vs-essential-tremor, HTML: https://parkinsonspathways.com/learn/parkinsons-vs-essential-tremor, Markdown: https://parkinsonspathways.com/learn/parkinsons-vs-essential-tremor.md
- levodopa-vs-dopamine-agonists, HTML: https://parkinsonspathways.com/learn/levodopa-vs-dopamine-agonists, Markdown: https://parkinsonspathways.com/learn/levodopa-vs-dopamine-agonists.md
- carbidopa-levodopa-formulations-compared, HTML: https://parkinsonspathways.com/learn/carbidopa-levodopa-formulations-compared, Markdown: https://parkinsonspathways.com/learn/carbidopa-levodopa-formulations-compared.md
- glp1-drugs-parkinsons-research, HTML: https://parkinsonspathways.com/learn/glp1-drugs-parkinsons-research, Markdown: https://parkinsonspathways.com/learn/glp1-drugs-parkinsons-research.md
- tavapadon-new-parkinsons-drug-2026, HTML: https://parkinsonspathways.com/learn/tavapadon-new-parkinsons-drug-2026, Markdown: https://parkinsonspathways.com/learn/tavapadon-new-parkinsons-drug-2026.md
- state-of-parkinsons-clinical-trials, HTML: https://parkinsonspathways.com/learn/state-of-parkinsons-clinical-trials, Markdown: https://parkinsonspathways.com/learn/state-of-parkinsons-clinical-trials.md
- where-parkinsons-clinical-trials-happen, HTML: https://parkinsonspathways.com/learn/where-parkinsons-clinical-trials-happen, Markdown: https://parkinsonspathways.com/learn/where-parkinsons-clinical-trials-happen.md

## PD Curated: Caregiver Guides (Markdown twins)

Family-first guides for Parkinson's caregivers, available as both HTML (for humans) and Markdown (for LLM ingestion).

- The First Things to Do When You Become a Caregiver, HTML: https://parkinsonspathways.com/caregivers/first-things-to-do-when-you-become-a-caregiver, Markdown: https://parkinsonspathways.com/caregivers/first-things-to-do-when-you-become-a-caregiver.md
- Building Your Person's Care Team, HTML: https://parkinsonspathways.com/caregivers/building-your-persons-care-team, Markdown: https://parkinsonspathways.com/caregivers/building-your-persons-care-team.md
- Talking to Kids About a Parent's or Grandparent's Parkinson's, HTML: https://parkinsonspathways.com/caregivers/talking-to-kids-about-a-parents-parkinsons, Markdown: https://parkinsonspathways.com/caregivers/talking-to-kids-about-a-parents-parkinsons.md
- Anticipatory Grief: Mourning Someone Who Is Still Here, HTML: https://parkinsonspathways.com/caregivers/anticipatory-grief-parkinsons-caregiver, Markdown: https://parkinsonspathways.com/caregivers/anticipatory-grief-parkinsons-caregiver.md
- Managing Medication Schedules When Timing Actually Matters, HTML: https://parkinsonspathways.com/caregivers/managing-medication-schedules-parkinsons, Markdown: https://parkinsonspathways.com/caregivers/managing-medication-schedules-parkinsons.md
- Caregiver Burnout Is Not a Character Flaw, HTML: https://parkinsonspathways.com/caregivers/caregiver-burnout-is-not-a-character-flaw, Markdown: https://parkinsonspathways.com/caregivers/caregiver-burnout-is-not-a-character-flaw.md
- Power of Attorney and Advance Directives: Do It Now, Not Later, HTML: https://parkinsonspathways.com/caregivers/power-of-attorney-and-advance-directives-parkinsons, Markdown: https://parkinsonspathways.com/caregivers/power-of-attorney-and-advance-directives-parkinsons.md
- When Your Person Can't Consent: Legal and Ethical Considerations for Trial Enrollment, HTML: https://parkinsonspathways.com/caregivers/when-your-person-cant-consent-clinical-trial-enrollment, Markdown: https://parkinsonspathways.com/caregivers/when-your-person-cant-consent-clinical-trial-enrollment.md
- Your Role During a Clinical Trial: What to Expect as the Care Partner, HTML: https://parkinsonspathways.com/caregivers/your-role-during-a-clinical-trial-care-partner, Markdown: https://parkinsonspathways.com/caregivers/your-role-during-a-clinical-trial-care-partner.md

## PD Curated: Trial Pages (Markdown twins)

Every recruiting Parkinson's trial has a Markdown twin at `/trial/{nctId}.md` containing the AI summary, five-word goal, plain-language eligibility, geocoded sites, contact info, and recent site changes (last 30 days). Append `.md` to any `/trial/{nctId}` URL in the sitemap to reach its twin; below are the 50 most recently updated for quick discovery.

- Quantification tools for a novel tau PET marker in a rare neurological disease: 18F-PI-2620 in progressive supranuclear palsy (EUCT-2023-508718-40-00), HTML: https://parkinsonspathways.com/trial/EUCT-2023-508718-40-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2023-508718-40-00.md
- Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients with Parkinson's Disease (ROCK-PD) (EUCT-2024-517413-33-00), HTML: https://parkinsonspathways.com/trial/EUCT-2024-517413-33-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2024-517413-33-00.md
- Accurately diagnose Lewy body dementia (NCT06120049), HTML: https://parkinsonspathways.com/trial/NCT06120049, Markdown: https://parkinsonspathways.com/trial/NCT06120049.md
- Effect of Exenatide on disease progression in early Parkinson’s disease. (EUCT-2024-520069-30-00), HTML: https://parkinsonspathways.com/trial/EUCT-2024-520069-30-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2024-520069-30-00.md
- Multicenter, randomized, double-blind, and placebo-controlled clinical trial to assess the efficacy and safety of donepezil versus placebo in mild cognitive impairment associated with Parkinson's disease. (EUCT-2024-510959-35-00), HTML: https://parkinsonspathways.com/trial/EUCT-2024-510959-35-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2024-510959-35-00.md
- Pathophysiology of pain in Parkinson's disease: exploration of the serotonin system in positron emission tomography (EUCT-2022-501123-24-00), HTML: https://parkinsonspathways.com/trial/EUCT-2022-501123-24-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2022-501123-24-00.md
- Patient- and care-related benefits of amyloid PET imaging (ENABLE) (EUCT-2023-503705-10-00), HTML: https://parkinsonspathways.com/trial/EUCT-2023-503705-10-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2023-503705-10-00.md
- PsyPal; Psilocybin Therapy for Psychological Distress in Palliative Patients (EUCT-2023-510488-36-01), HTML: https://parkinsonspathways.com/trial/EUCT-2023-510488-36-01, Markdown: https://parkinsonspathways.com/trial/EUCT-2023-510488-36-01.md
- A Phase 3b open-label, randomised study of IPX203 in subjects with advanced Parkinson’s disease and motor fluctuations - ADIP study (EUCT-2025-521772-57-00), HTML: https://parkinsonspathways.com/trial/EUCT-2025-521772-57-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2025-521772-57-00.md
- A study of safety and tolerability (acceptability of potential side effects) of exidavnemab, at 2 different doses, in patients with Parkinson’s disease and in Patients with Multiple System Atrophy (EUCT-2024-511222-30-00), HTML: https://parkinsonspathways.com/trial/EUCT-2024-511222-30-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2024-511222-30-00.md
- An adaptive, Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson’s disease (EUCT-2022-500292-31-00), HTML: https://parkinsonspathways.com/trial/EUCT-2022-500292-31-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2022-500292-31-00.md
- Research into the safety of a new agent (NRG5051) in healthy adults and patients with Parkinson's disease or ALS (EUCT-2025-523872-22-00), HTML: https://parkinsonspathways.com/trial/EUCT-2025-523872-22-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2025-523872-22-00.md
- Detect brain alpha synuclein deposits (NCT06891703), HTML: https://parkinsonspathways.com/trial/NCT06891703, Markdown: https://parkinsonspathways.com/trial/NCT06891703.md
- Measure heat shock protein levels (NCT07380204), HTML: https://parkinsonspathways.com/trial/NCT07380204, Markdown: https://parkinsonspathways.com/trial/NCT07380204.md
- Montelukast as disease modifying treatment in mild-moderate Parkinson’s disease (MONTPARK), a double-blind randomized placebo-controlled phase II trial (EUCT-2023-504278-39-00), HTML: https://parkinsonspathways.com/trial/EUCT-2023-504278-39-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2023-504278-39-00.md
- A trial to determine the safety and tolerability of transplanted stem cellderived dopamine neurons to the brains of individuals with Parkinson's Disease. (EUCT-2024-511237-35-00), HTML: https://parkinsonspathways.com/trial/EUCT-2024-511237-35-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2024-511237-35-00.md
- A Phase 2 study to assess the safety and efficacy of SUL-238 in patients with early, untreated Parkinson’s Disease (EUCT-2025-524674-42-00), HTML: https://parkinsonspathways.com/trial/EUCT-2025-524674-42-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2025-524674-42-00.md
- Slow early Parkinson disease progression (NCT06680830), HTML: https://parkinsonspathways.com/trial/NCT06680830, Markdown: https://parkinsonspathways.com/trial/NCT06680830.md
- Reduce overactive dopamine related behaviors (NCT07151378), HTML: https://parkinsonspathways.com/trial/NCT07151378, Markdown: https://parkinsonspathways.com/trial/NCT07151378.md
- A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA) (EUCT-2023-504472-24-00), HTML: https://parkinsonspathways.com/trial/EUCT-2023-504472-24-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2023-504472-24-00.md
- Phase 2 Study of CVN424 (EUCT-2024-516811-25-00), HTML: https://parkinsonspathways.com/trial/EUCT-2024-516811-25-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2024-516811-25-00.md
- New drug to slow Parkinson (NCT04691661), HTML: https://parkinsonspathways.com/trial/NCT04691661, Markdown: https://parkinsonspathways.com/trial/NCT04691661.md
- Slow early Parkinson disease progression (NCT07174310), HTML: https://parkinsonspathways.com/trial/NCT07174310, Markdown: https://parkinsonspathways.com/trial/NCT07174310.md
- A Study in Adults with Parkinson's Disease and a Lack of Interest or Motivation to Test How Different Doses of IRL757 Given for Multiple Days are Tolerated in the Body (EUCT-2025-523612-37-00), HTML: https://parkinsonspathways.com/trial/EUCT-2025-523612-37-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2025-523612-37-00.md
- A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson’s Disease (BeyoND) (EUCT-2024-513548-27-00), HTML: https://parkinsonspathways.com/trial/EUCT-2024-513548-27-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2024-513548-27-00.md
- Test safety of spinal medication (NCT06565195), HTML: https://parkinsonspathways.com/trial/NCT06565195, Markdown: https://parkinsonspathways.com/trial/NCT06565195.md
- To investigate the safety and efficacy of a novel investigational compound against neurological diseases such as Parkinson's disease in healthy men and women and patients with Parkinson's disease. (EUCT-2025-521357-17-00), HTML: https://parkinsonspathways.com/trial/EUCT-2025-521357-17-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2025-521357-17-00.md
- First in human study in healthy volunteers and participants with Parkinsons disease with and without GBA1 mutations. (EUCT-2023-509158-68-00), HTML: https://parkinsonspathways.com/trial/EUCT-2023-509158-68-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2023-509158-68-00.md
- GREAT; GRoningen Early-PD Ambroxol Treatment Trial (EUCT-2024-514976-41-00), HTML: https://parkinsonspathways.com/trial/EUCT-2024-514976-41-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2024-514976-41-00.md
- New medication slows Parkinson progression (NCT06976268), HTML: https://parkinsonspathways.com/trial/NCT06976268, Markdown: https://parkinsonspathways.com/trial/NCT06976268.md
- A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease. (EUCT-2024-511110-21-00), HTML: https://parkinsonspathways.com/trial/EUCT-2024-511110-21-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2024-511110-21-00.md
- A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease (EUCT-2023-507132-21-00), HTML: https://parkinsonspathways.com/trial/EUCT-2023-507132-21-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2023-507132-21-00.md
- Reduce harmful brain protein levels (NCT07216066), HTML: https://parkinsonspathways.com/trial/NCT07216066, Markdown: https://parkinsonspathways.com/trial/NCT07216066.md
- Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson’s Disease (LRRK2-PD) (EUCT-2024-513384-15-00), HTML: https://parkinsonspathways.com/trial/EUCT-2024-513384-15-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2024-513384-15-00.md
- Management of Parkinson's disease if levodopa is broken down prematurely (EUCT-2024-510629-24-00), HTML: https://parkinsonspathways.com/trial/EUCT-2024-510629-24-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2024-510629-24-00.md
- A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson's disease (BouNDless) (EUCT-2024-511940-20-00), HTML: https://parkinsonspathways.com/trial/EUCT-2024-511940-20-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2024-511940-20-00.md
- Research into the safety of a new agent (AX-5006) in people with and without Parkinson's disease. (EUCT-2025-523254-14-00), HTML: https://parkinsonspathways.com/trial/EUCT-2025-523254-14-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2025-523254-14-00.md
- Pharmacologically modulating the noradrenergic arousal system to reduce freezing of gait in Parkinson’s disease: a multi-center and multi-modal approach. (EUCT-2024-516756-18-00), HTML: https://parkinsonspathways.com/trial/EUCT-2024-516756-18-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2024-516756-18-00.md
- Exploratory study of the expression of the serotonergic 5-HT4 receptor in Parkinson's disease (EUCT-2022-503089-57-00), HTML: https://parkinsonspathways.com/trial/EUCT-2022-503089-57-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2022-503089-57-00.md
- Multicenter, randomized, double-blind, parallel-group clinical trial to evaluate the efficacy and safety of Safinamide versus Rasagiline in fatigue associated with Parkinson's Disease. (EUCT-2023-503713-29-00), HTML: https://parkinsonspathways.com/trial/EUCT-2023-503713-29-00, Markdown: https://parkinsonspathways.com/trial/EUCT-2023-503713-29-00.md
- Assess balance confidence and fear (NCT06751797), HTML: https://parkinsonspathways.com/trial/NCT06751797, Markdown: https://parkinsonspathways.com/trial/NCT06751797.md
- Brain stimulation improves sentence understanding (NCT07449117), HTML: https://parkinsonspathways.com/trial/NCT07449117, Markdown: https://parkinsonspathways.com/trial/NCT07449117.md
- Improve side to side balance (NCT07568951), HTML: https://parkinsonspathways.com/trial/NCT07568951, Markdown: https://parkinsonspathways.com/trial/NCT07568951.md
- Reduce gait freezing with cueing (NCT06733077), HTML: https://parkinsonspathways.com/trial/NCT06733077, Markdown: https://parkinsonspathways.com/trial/NCT06733077.md
- Reduce apathy and boost motivation (NCT07399496), HTML: https://parkinsonspathways.com/trial/NCT07399496, Markdown: https://parkinsonspathways.com/trial/NCT07399496.md
- Improve walking endurance through exercise (NCT07221266), HTML: https://parkinsonspathways.com/trial/NCT07221266, Markdown: https://parkinsonspathways.com/trial/NCT07221266.md
- Reduce freezing during walking remotely (NCT06957405), HTML: https://parkinsonspathways.com/trial/NCT06957405, Markdown: https://parkinsonspathways.com/trial/NCT06957405.md
- Reduce nighttime awakenings with stimulation (NCT05070013), HTML: https://parkinsonspathways.com/trial/NCT05070013, Markdown: https://parkinsonspathways.com/trial/NCT05070013.md
- Boost brain energetics using exercise (NCT04426786), HTML: https://parkinsonspathways.com/trial/NCT04426786, Markdown: https://parkinsonspathways.com/trial/NCT04426786.md
- Improve gait using Percept neurostimulation (NCT05820074), HTML: https://parkinsonspathways.com/trial/NCT05820074, Markdown: https://parkinsonspathways.com/trial/NCT05820074.md

## Universal Raw Mirror (any condition)

A separate, condition-agnostic mirror of ClinicalTrials.gov. **Raw data only, no AI summaries, no PD-specific filtering, no editorial enrichment.** Use this when you want source-of-truth data with field-level change tracking.

- URL pattern: https://parkinsonspathways.com/agent/trials/{nctId}.md
- Authoritative source: https://clinicaltrials.gov/study/{nctId}

## Agent API

A programmatic API namespace for agents and downstream services is in the works. Entry point will live at `https://parkinsonspathways.com/api/agent/` and will expose change feeds, matching, and replay endpoints. Until that ships, retrieve content via the Markdown URLs above.

## Machine-Readable Resources

- [Sitemap](https://parkinsonspathways.com/sitemap.xml), clean HTML URLs for every public page (only `/trial/{nctId}`, `/learn/{slug}`, `/trials-near-me`, `/trials-near-me/{city}`, `/trials/{type}/{slug}`, and `/trials/eu/{euctId}` entries support a `.md` twin)
- [Sitemap Index](https://parkinsonspathways.com/sitemap-index.xml), references the main sitemap
- [Full LLM Context](https://parkinsonspathways.com/llms-full.txt)